<DOC>
	<DOCNO>NCT01621633</DOCNO>
	<brief_summary>This study characterize pharmacokinetics well safety tolerability single oral dose LCZ696 200 mg subject mild moderate hepatic impairment compare match healthy subject</brief_summary>
	<brief_title>A Study LCZ696 Subjects With Mild Moderate Hepatic Impairment Compared With Normal Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<criteria>All subject : Male female subject age 1875 year . Body weight least 55 kg body mass index 1835 kg/m2 . Hepatic impairment subject : Mild moderate hepatic impairment . All subject : Clinical manifestation postural symptomatic hypotension screen baseline . History hypersensitivity LCZ696 drug similar class . Hepatic impairment subject : Hepatic impairment due nonliver disease . Treatment vasodilator , autonomic alpha blocker beta2 agonist within 2 week dose . Encephalopathyy Stage III IV . Primary biliary liver cirrhosis biliary obstruction . History gastrointestinal bleeding within 3 month prior screen . Healthy subject : Any surgical medical condition might significantly alter distribution , excretion drug , may jeopardize subject case participation study . Use prescription drug , herbal supplement , and/or overthecounter medication , dietary supplement ( vitamin include ) within 2 week prior initial dosing . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>hepatic impairment</keyword>
</DOC>